Nuvation Bio Inc. (NUVB) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
5.63
↑+88% vs avg
5yr avg: 3.00
30Y Low0.5·High11.8
ROE
↓
-53.2%
↑-30% vs avg
5yr avg: -40.9%
30Y Low-106%·High-12%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NUVB Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Nuvation Bio Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.7B | $3.1B | $715M | $331M | $416M | $1.7B | $2.5B | — | — |
| Enterprise Value | $1.6B | $2.9B | $688M | $292M | $319M | $1.6B | $2.5B | — | — |
| P/E Ratio → | -8.40 | — | — | — | — | — | — | — | — |
| P/S Ratio | 27.82 | 48.65 | 90.81 | — | — | — | — | — | — |
| P/B Ratio | 5.63 | 10.01 | 1.54 | 0.55 | 0.64 | 2.25 | 11.84 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NUVB EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 46.20 | 87.40 | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
NUVB Profitability
Margins and return-on-capital ratios measuring operating efficiency
Nuvation Bio Inc. earns an operating margin of -338.7%. Operating margins have expanded from -7527.3% to -338.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -53.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.6% | 86.6% | 10.1% | — | — | — | — | — | — |
| Operating Margin | -338.7% | -338.7% | -7527.3% | — | — | — | — | — | — |
| Net Profit Margin | -325.3% | -325.3% | -7213.8% | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -53.2% | -53.2% | -106.3% | -12.0% | -14.9% | -18.1% | -25.0% | -57.4% | — |
| ROA | -36.0% | -36.0% | -97.7% | -11.7% | -14.4% | -17.4% | -24.3% | -55.4% | -627.8% |
| ROIC | -54.3% | -54.3% | -88.6% | -13.3% | -15.3% | -17.5% | -21.8% | -42.2% | — |
| ROCE | -42.8% | -42.8% | -108.7% | -15.8% | -16.9% | -19.2% | -26.2% | -54.9% | — |
NUVB Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $164M exceeds total debt of $10M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.50 | -0.06 | -0.06 | -0.15 | -0.17 | -0.14 | -0.03 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -13.96 | -13.96 | -1664.51 | — | — | — | — | — | — |
Net cash position: cash ($164M) exceeds total debt ($10M)
NUVB Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Nuvation Bio Inc.'s current ratio of 6.95x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 44.11x to 6.95x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.95 | 6.95 | 9.04 | 44.11 | 50.70 | 45.62 | 33.69 | 37.42 | 0.18 |
| Quick Ratio | 6.81 | 6.81 | 9.04 | 44.11 | 50.70 | 45.62 | 33.69 | 37.42 | 0.18 |
| Cash Ratio | 6.44 | 6.44 | 8.63 | 43.74 | 50.23 | 45.22 | 32.93 | 37.10 | 0.15 |
| Asset Turnover | — | 0.11 | 0.01 | — | — | — | — | — | — |
| Inventory Turnover | 0.74 | 0.74 | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 112.35 | 755.31 | — | — | — | — | — | — |
NUVB Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Nuvation Bio Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $342M | $269M | $219M | $217M | $198M | $218M | $207M | $184M |
Peer Comparison
Compare NUVB with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NUVBYou | $2B | -8.4 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 TPST | $56M | -1.3 | — | — | — | — | -182.3% | -507.5% | — |
 PRAX | $8B | -25.1 | — | — | — | — | -45.8% | -65.0% | — |
 RVMD | $32B | -25.4 | — | — | — | — | -58.1% | -54.3% | — |
 AUPH | $2B | 7.8 | 20.4 | 15.9 | 88.5% | 37.1% | 59.9% | 16.6% | 0.7 |
 IMVT | $6B | -10.5 | — | — | — | — | -62.5% | — | — |
 ARVN | $656M | -8.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 KRYS | $9B | 42.2 | 47.8 | 45.1 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 PTGX | $7B | -50.7 | — | 118.3 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 FOLD | $4B | -80.5 | 140.6 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See NUVB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NUVB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NUVB vs KYMR
Side-by-side business, growth, and profitability comparison vs Kymera Therapeutics, Inc..
Start ComparisonNUVB — Frequently Asked Questions
Quick answers to the most common questions about buying NUVB stock.
What is Nuvation Bio Inc.'s P/E ratio?
Nuvation Bio Inc.'s current P/E ratio is -8.4x. This places it at the 50th percentile of its historical range.
What is Nuvation Bio Inc.'s ROE?
Nuvation Bio Inc.'s return on equity (ROE) is -53.2%. The historical average is -41.0%.
Is NUVB stock overvalued?
Based on historical data, Nuvation Bio Inc. is trading at a P/E of -8.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Nuvation Bio Inc.'s profit margins?
Nuvation Bio Inc. has 86.6% gross margin and -338.7% operating margin.